All In Biotech

Investigational drug · Phase 2

iPSC

Also called: human allogeneic induced pluripotent stem cell -derived dopaminergic neural progenitor cell, Allogeneic Human Induced Pluripotent Stem Cell -Derived Motor Neuron Progenitor Cells

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Spinal Cord Injury, Safety, Efficacy.

Phase 2

Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

3

3 still active

All registered trials

85

Any phase or sponsor naming "iPSC"

First trial start

2025

Aug 5, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "iPSC", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Spinal Cord Injury
  • Safety
  • Efficacy
  • Clinical Trial
  • Induced Pluripotent Stem Cells
  • Human Motor Neuron Progenitor
  • Transplantation
  • RCT
  • Parkinson Disease (PD)
  • Parkinson's Disease

Approved drugs for the same conditions: Parkinson's disease · Neurology

Largest trials

Live from ClinicalTrials.gov: studies naming "iPSC" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 16,389 on PubMed

Also in development for Spinal Cord Injury

  • EG110APhase 22 trials

    Cyllene Therapeutics · Neurogenic Detrusor Overactivity, Spinal Cord Injuries, Urinary Bladder, Overactive

  • UnasnemabMT-3921Phase 21 trial

    Tanabe Pharma America, Inc. · Spinal Cord Injury

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.